It is important to understand that your physiology is unique
Nausea, constipation, and appetite loss are expected and manageable
In order of frequency, the DPP4 inhibitors with less symptomatic association are vildagliptin, alogliptin, sitagliptin, saxagliptin, linagliptin, and teneligliptin.42 SGLT2 inhibitors As with the DPP4 inhibitors, the SGLT2 inhibitors have not been associated with gastrointestinal adverse effects, or their association is minimal
The aim of this paper is to provide experience-based guidance on multimodal nonsurgical aesthetic treatment of the face and neck in patients undergoing weight loss with GLP-1-based therapies
The answer came from Novo Nordisk, who engineered liraglutide (Victoza, FDA approved January 2010) by attaching a C16 fatty acid chain to a modified GLP-1 backbone